NASDAQ:IVA Inventiva Q2 2026 TU Earnings Report $3.53 +0.16 (+4.75%) Closing price 09/28/2026 04:00 PM EasternExtended Trading$3.58 +0.05 (+1.33%) As of 09/28/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Inventiva EPS ResultsActual EPS-$0.15Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AInventiva Revenue ResultsActual Revenue$0.75 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInventiva Announcement DetailsQuarterQ2 2026 TUDate8/14/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesPress Release (6-K)Press ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Press Release Inventiva Earnings HeadlinesInventiva S.A. (IVA) Q2 2026 Earnings Call TranscriptSeptember 28 at 4:00 PM | seekingalpha.comInventiva S.A. 2026 Q2 - Results - Earnings Call PresentationSeptember 28 at 2:31 PM | seekingalpha.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Inventiva overtreft Q2 2026-verwachtingen, maar beleggers blijven voorzichtigSeptember 28 at 12:51 PM | nl.investing.comInventiva第二季度业绩超预期，投资者仍保持谨慎September 28 at 12:51 PM | cn.investing.comInventiva S.A. Reports Earnings Results for the Half Year Ended June 30, 2026September 28 at 12:51 PM | marketscreener.comMSee More Inventiva Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Inventiva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inventiva and other key companies, straight to your email. Email Address About InventivaInventiva (NASDAQ:IVA) S.A. is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options. Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development. Lanifibranor is not an approved medicine. Founded in 2011, Inventiva conducts its research and development activities primarily in France and works through international clinical-development programs. The company’s American depositary shares trade on the Nasdaq Capital Market under the symbol IVA, while its ordinary shares are listed on Euronext Paris.View Inventiva ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindFertilizer Prices Keep Climbing: 3 Stocks Still Trading at a Discount Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
